Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy
We identified several soluble immune mediators as pre-treatment and on-treatment biomarkers of survival in patients with NSCLC treated with ICI monotherapy. Some of these biomarkers were associated with other possible predictors, including irAE development, PD-L1 expression, CD8+ TIL density and NLR. Further large-scale studies are needed to establish biomarkers for patients with NSCLC who received ICI monotherapy.
Authors
- Kenta Murotani (ORCID: https://orcid.org/0000-0003-0623-9365)
- Koichi Azuma (ORCID: https://orcid.org/0000-0001-5040-5856)
- Tomoaki Hoshino (ORCID: https://orcid.org/0000-0002-0459-4913)
- Akihiko Kawahara (ORCID: https://orcid.org/0000-0002-4081-2519)
- Yuuya Nishii
- Tetsuro Sasada (ORCID: https://orcid.org/0000-0003-3262-8559)
- Takaaki Tokito (ORCID: https://orcid.org/0000-0002-8429-2287)
- Daiki Murata (ORCID: https://orcid.org/0000-0002-4295-5046)
Institutions
- Kurume University (JP)
- Kanagawa Prefectural Hospital Organization (JP)
- Kanagawa Cancer Center
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1007/s00262-024-03781-8
- Citations
- 8
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.26
Funders
- Japan Agency for Medical Research and Development